Drug Monograph

Drug/Drug Class:	**SUPPRELIN LA™ (histrelin acetate) subcutaneous implant/ GnRH Antagonist**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each implant of Supprelin LA™ contains 50 mg of histrelin acetate intended to deliver 65 mcg/day for a 12 month period.
Manufacturer:	Endo Pharmaceuticals Solutions, Inc., Malvern, PA 19355 USA
Indications:	Supprelin LA™ is a gonadotropin releasing hormone antagonist indicated for the treatment of central precocious puberty in children.
Costs:	$21,115.48 per kit of Supprelin LA™ Maximum Allowable Cost
Summary of Findings:	The MO HealthNet Division recommends prior authorization status for this product.
Status Recommendation:	☒ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☐ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Abbey Mahaney, Pharm. D. 2015
Date: October 23, 2014

© 2014 Xerox Heritage, LLC All Rights Reserved.